SynbioTech Targets GLP-1 Weight-Loss Boom with New Nutrition Platform

**BANGKOK** – As blockbuster GLP-1 drugs like Ozempic and Wegovy change how millions manage weight, a biotech firm is moving to solve a side effect of the trend: muscle loss and poor nutrition. SynbioTech announced it will present its TWK10® probiotic strain and a new microbiome-based CDMO (contract development and manufacturing) platform at Vitafoods Asia 2026. The company is positioning these offerings specifically for the emerging "GLP-1 companion-nutrition" market. GLP-1 therapies suppress appetite, but they often lead to reduced food intake overall, which can cause users to lose muscle mass and miss essential nutrients. SynbioTech’s platform aims to help brands create supplements that support body composition and metabolic health during weight-loss treatment. The company will showcase how its CDMO service allows other firms to develop and scale microbiome-focused nutritional products quickly. The announcement comes as food and supplement makers race to serve patients who are actively using these injectable medications. The presentation is scheduled for the upcoming Vitafoods Asia trade show, a key event for the nutraceutical industry.